

Katrina A B Goddard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2172365/publications.pdf>

Version: 2024-02-01

46
papers

1,565
citations

304368

22
h-index

315357

38
g-index

47
all docs

47
docs citations

47
times ranked

2806
citing authors

#	ARTICLE	IF	CITATIONS
1	ClinGen™s Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents. <i>Genetics in Medicine</i> , 2022, 24, 1328-1335.	1.1	4
2	Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 17.	0.6	4
3	Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders. <i>Genetics in Medicine</i> , 2019, 21, 2561-2568.	1.1	4
4	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. <i>Familial Cancer</i> , 2019, 18, 317-325.	0.9	6
5	Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 31.	0.6	14
6	The evolving landscape of expanded carrier screening: challenges and opportunities. <i>Genetics in Medicine</i> , 2019, 21, 790-797.	1.1	90
7	Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. <i>Genetics in Medicine</i> , 2018, 20, 1186-1195.	1.1	11
8	Time Costs for Genetic Counseling in Preconception Carrier Screening with Genome Sequencing. <i>Journal of Genetic Counseling</i> , 2018, 27, 823-833.	0.9	22
9	Patient perspectives on the use of categories of conditions for decision making about genomic carrier screening results. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 376-385.	0.7	21
10	Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group. <i>Human Mutation</i> , 2018, 39, 1677-1685.	1.1	34
11	Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 898-909.	0.6	15
12	Lessons Learned From A Study Of Genomics-Based Carrier Screening For Reproductive Decision Making. <i>Health Affairs</i> , 2018, 37, 809-816.	2.5	10
13	Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening. <i>PLoS ONE</i> , 2018, 13, e0200139.	1.1	19
14	Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. <i>American Journal of Human Genetics</i> , 2018, 102, 1078-1089.	2.6	35
15	Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. <i>Genetics in Medicine</i> , 2017, 19, 803-808.	1.1	24
16	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. <i>Familial Cancer</i> , 2017, 16, 377-387.	0.9	11
17	Reasons for Declining Preconception Expanded Carrier Screening Using Genome Sequencing. <i>Journal of Genetic Counseling</i> , 2017, 26, 971-979.	0.9	37
18	Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing. <i>Contemporary Clinical Trials</i> , 2017, 53, 100-105.	0.8	26

#	ARTICLE	IF	CITATIONS
19	The NextGen Study: patient motivation for participation in genome sequencing for carrier status. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 508-515.	0.6	20
20	A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. <i>Genetics in Medicine</i> , 2017, 19, 575-582.	1.1	68
21	Generating a taxonomy for genetic conditions relevant to reproductive planning. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 565-573.	0.7	25
22	A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. <i>Genetics in Medicine</i> , 2016, 18, 1258-1268.	1.1	89
23	Patients' ratings of genetic conditions validate a taxonomy to simplify decisions about preconception carrier screening via genome sequencing. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 574-582.	0.7	20
24	It's Worth Knowing? Focus Group Participants' Perceived Utility of Genomic Preconception Carrier Screening. <i>Journal of Genetic Counseling</i> , 2016, 25, 135-145.	0.9	44
25	It's complicated: criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 239-242.	0.6	19
26	Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. <i>BMC Cancer</i> , 2015, 15, 156.	1.1	81
27	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. <i>Cancer</i> , 2015, 121, 3281-3289.	2.0	30
28	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. <i>American Journal of Human Genetics</i> , 2014, 94, 818-826.	2.6	342
29	Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. <i>Genetics in Medicine</i> , 2013, 15, 721-728.	1.1	40
30	Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. <i>Journal of the National Cancer Institute</i> , 2013, 105, 929-936.	3.0	30
31	Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. <i>Genetics in Medicine</i> , 2013, 15, 933-940.	1.1	45
32	Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 673-680.	1.1	19
33	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. <i>Genetics in Medicine</i> , 2012, 14, 633-642.	1.1	36
34	Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. <i>Genetics in Medicine</i> , 2012, 14, 656-662.	1.1	24
35	Utilization of HER2 genetic testing in a multi-institutional observational study. <i>American Journal of Managed Care</i> , 2012, 18, 704-12.	0.8	10
36	A Confidence-Limit-Based Approach to the Assessment of Hardy-Weinberg Equilibrium. <i>Biometrical Journal</i> , 2010, 52, 253-270.	0.6	15

#	ARTICLE	IF	CITATIONS
37	Dengue hemorrhagic fever is associated with polymorphisms in JAK1. <i>European Journal of Human Genetics</i> , 2010, 18, 1221-1227.	1.4	45
38	Association mapping by generalized linear regression with density-based haplotype clustering. <i>Genetic Epidemiology</i> , 2009, 33, 16-26.	0.6	6
39	Adapting the logical basis of tests for Hardy-Weinberg Equilibrium to the real needs of association studies in human and medical genetics. <i>Genetic Epidemiology</i> , 2009, 33, 569-580.	0.6	9
40	Public Awareness and Use of Direct-to-Consumer Genetic Tests: Results From 3 State Population-Based Surveys, 2006. <i>American Journal of Public Health</i> , 2009, 99, 442-445.	1.5	37
41	Awareness and use of direct-to-consumer nutrigenomic tests, United States, 2006. <i>Genetics in Medicine</i> , 2007, 9, 510-517.	1.1	56
42	Density-based clustering in haplotype analysis for association mapping. <i>BMC Proceedings</i> , 2007, 1, S27.	1.8	5
43	Issues in association mapping with high-density SNP data and diverse family structures. <i>Genetic Epidemiology</i> , 2007, 31, S22-S33.	0.6	4
44	HLA-DQA Is Associated with Abdominal Aortic Aneurysms in the Belgian Population. <i>Annals of the New York Academy of Sciences</i> , 2006, 1085, 392-395.	1.8	9
45	Beta 2 adrenergic receptor polymorphisms in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2005, 39, 544-550.	1.0	16
46	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. <i>Neurogenetics</i> , 2004, 5, 121-128.	0.7	27